Baidu
map

JACC:心绞痛对于冠心病、心衰、左室收缩功能不全患者的重要性

2015-11-03 崔倩 译 MedSci原创

左心室(LV)收缩功能不全,冠状动脉疾病(CAD),心绞痛患者往往被认为比那些没有心绞痛的患者有更坏的预后,但能从冠状动脉旁路移植术(CABG)手术有更大的预后益处。这项研究调查了:1)是否心绞痛与预后较差相关; 2)是否心绞痛确定哪些患者可以从CABG手术获得更大的生存益处;3)CABG是否改善LV收缩功能障碍和CAD的心绞痛患者临床效果。研究人员进行了STICH(外科治疗缺血性心力衰竭)试验,

左心室(LV)收缩功能不全,冠状动脉疾病(CAD)的患者发生心绞痛往往被认为比那些没有心绞痛的患者有更坏的预后,但能从冠状动脉旁路移植术(CABG)手术有更大的预后益处。

这项研究调查了:1)心绞痛是否与预后较差相关; 2)心绞痛是否可以确定哪些患者可以从CABG手术获得更大的生存益处;3)CABG是否改善LV收缩功能障碍和CAD患者的心绞痛的临床效果。

研究人员进行了STICH(外科治疗缺血性心力衰竭)试验,其中1212例射血分数≤35%和CAD患者被随机分配接受CABG或药物治疗的。多变量Cox和逻辑模型被用来评估长期的临床结果。

在基线时,770例患者(64%)报告有心绞痛。在分配到药物治疗的患者中,有和无心绞痛患者的全因死亡率相似(风险比[HR]:1.05;95%可信区间(Cl):0.79〜1.38)。患者是否有心绞痛CABG的效果是相似的:有心绞痛(HR:0.89;95%Cl:0.71〜1.13),无心绞痛(HR:0.68;95%Cl:0.50〜0.94,相互P=0.14)。分配到CABG的患者更可能比那些分配到单纯药物治疗的患者改善心绞痛(比值比:0.70;95%Cl:0.55〜0.90;P<0.01)。

心绞痛不能预测药物治疗左室收缩功能不全和冠状动脉疾病患者的各种原因的死亡率,也不能确定哪些患者可以从CABG获得更大的生存益处。然而,CABG手术确实比单独药物治疗能更大的程度的改善心绞痛。

原始出处:

E. Marc Jolicœur,Allison Dunning,Serenella Castelvecchio,et al.Importance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction,JACC,2015.11.3

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1942427, encodeId=e067194242e31, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 05 21:41:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853438, encodeId=7a4d18534381b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Nov 11 14:41:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325133, encodeId=3fcc13251333c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Nov 05 04:41:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42529, encodeId=66cc42529e0, content=翻译的好生硬, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=087a1624490, createdName=Yangxiaobo, createdTime=Wed Nov 04 14:58:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42449, encodeId=f69b424495f, content=左室收缩功能不全患者需注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1a01625167, createdName=zhouxue1990, createdTime=Tue Nov 03 22:31:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
    2016-05-05 mgqwxj
  2. [GetPortalCommentsPageByObjectIdResponse(id=1942427, encodeId=e067194242e31, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 05 21:41:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853438, encodeId=7a4d18534381b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Nov 11 14:41:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325133, encodeId=3fcc13251333c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Nov 05 04:41:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42529, encodeId=66cc42529e0, content=翻译的好生硬, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=087a1624490, createdName=Yangxiaobo, createdTime=Wed Nov 04 14:58:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42449, encodeId=f69b424495f, content=左室收缩功能不全患者需注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1a01625167, createdName=zhouxue1990, createdTime=Tue Nov 03 22:31:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
    2015-11-11 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1942427, encodeId=e067194242e31, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 05 21:41:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853438, encodeId=7a4d18534381b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Nov 11 14:41:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325133, encodeId=3fcc13251333c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Nov 05 04:41:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42529, encodeId=66cc42529e0, content=翻译的好生硬, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=087a1624490, createdName=Yangxiaobo, createdTime=Wed Nov 04 14:58:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42449, encodeId=f69b424495f, content=左室收缩功能不全患者需注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1a01625167, createdName=zhouxue1990, createdTime=Tue Nov 03 22:31:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1942427, encodeId=e067194242e31, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 05 21:41:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853438, encodeId=7a4d18534381b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Nov 11 14:41:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325133, encodeId=3fcc13251333c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Nov 05 04:41:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42529, encodeId=66cc42529e0, content=翻译的好生硬, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=087a1624490, createdName=Yangxiaobo, createdTime=Wed Nov 04 14:58:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42449, encodeId=f69b424495f, content=左室收缩功能不全患者需注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1a01625167, createdName=zhouxue1990, createdTime=Tue Nov 03 22:31:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
    2015-11-04 Yangxiaobo

    翻译的好生硬

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1942427, encodeId=e067194242e31, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu May 05 21:41:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853438, encodeId=7a4d18534381b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Nov 11 14:41:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325133, encodeId=3fcc13251333c, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Nov 05 04:41:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42529, encodeId=66cc42529e0, content=翻译的好生硬, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=087a1624490, createdName=Yangxiaobo, createdTime=Wed Nov 04 14:58:00 CST 2015, time=2015-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42449, encodeId=f69b424495f, content=左室收缩功能不全患者需注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1a01625167, createdName=zhouxue1990, createdTime=Tue Nov 03 22:31:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
    2015-11-03 zhouxue1990

    左室收缩功能不全患者需注意

    0

相关资讯

TCT2014:生物可吸收支架与Xience支架同样安全有效

TCT 2014年会最新临床试验专场上发布的ABSORB II研究中期分析结果显示,与依维莫司洗脱金属支架(Xience)相比,依维莫司生物可吸收支架(Absorb BVS)可显著降低冠状动脉疾病患者的早期管腔获得,且两者在早期管腔获得方面的差异与支架置入后的即刻支架回缩无关。但是,二者对临床结局及心绞痛状态的影响并无差异。 自获得欧洲CE认证后,虽未进行与金属支架的随机对比,但Absorb B

于泓:心绞痛药物治疗面面观

作者简介:于泓,心脏内科医生,博士毕业于北京大学医学部,留学德国2年。擅长冠心病、心律失常、心血管介入诊治,以及高血压、心力衰竭、心脏性猝死的防治、肺栓塞等疾病的诊治。 导读:所有针对冠心病的治疗都有相同的目标:提高生活质量,减轻症状,尤其是心绞痛。用于治疗冠心病、心绞痛的药物可以减少死亡的风险。选择吃药还是手术开通狭窄或阻塞的血管取决于患者个体情况。 心绞痛是冠状动脉供血

EMA新建议:依伐布雷定效果有待进一步监测

继药物警戒风险评估委员会(PRAC)评论后,欧洲药物管理局(EMA)对依伐布雷定治疗症状性心绞痛或心力衰竭提出了新建议。 该评论的依据是来自SIGNIFY(Study Assessing theMorbidity-Mortality Benefits of the If Inhibitor Ivabradine inPatients with Coronary Artery Diseas

治疗顽固性心绞痛的新思路——COSIRA研究结果正式发表

河北省人民医院 郭艺芳临床上,部分心绞痛患者经过最佳药物治疗后仍不能满意控制症状,且因种种原因不适于冠脉介入治疗,此时治疗难度会非常大。根据刚刚正式发表的2期临床试验结果,应用冠状窦支架有望显著缓解患者心绞痛症状并改善生活质量。相关阅读:NEJM:顽固性心绞痛患者的福音来了冠状窦支架是一种球囊膨胀式沙漏状特殊装置,置入冠状窦后可以增加局部血流阻力,进而增加缺血心肌的灌注压,缓解缺血相关症状。刚刚正

NEJM:顽固性心绞痛患者的福音来了

顽固性心绞痛患者的福音来了背景许多有冠心病的患者并不适合使用血管再生药物进行治疗顽固性心绞痛,尽管这一措施符合治疗标准。我们使用了一个利用气囊膨胀原理、不锈钢、沙漏形、减少冠状窦的新设备,将该设备放置在一个冠状窦最集中狭窄的部位,增加冠状窦压力,血液也因此分配到缺血心肌,采用这个原理治疗顽固性心绞痛。方式实验参与人员为104位由加拿大心血管协会(CCS)评定心功能为三级或者四级和心肌缺血的患者(心

Baidu
map
Baidu
map
Baidu
map